{
  "zip": "V6Z 1S4",
  "sector": "Healthcare",
  "longBusinessSummary": "iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.",
  "city": "Vancouver",
  "phone": "604 800 9860",
  "state": "BC",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.icotherapeutics.com",
  "maxAge": 1,
  "address1": "777 Hornby Street",
  "industry": "Biotechnology",
  "address2": "6th Floor",
  "previousClose": 0.0367,
  "regularMarketOpen": 0.0365,
  "twoHundredDayAverage": 0.03417266,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.03847,
  "navPrice": null,
  "averageDailyVolume10Day": 26400,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.0367,
  "fiftyDayAverage": 0.038939394,
  "trailingAnnualDividendRate": null,
  "open": 0.0365,
  "averageVolume10days": 26400,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 2.698349,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.0365,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 4025,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 6685239,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 11723,
  "priceToSalesTrailing12Months": null,
  "dayLow": 0.0365,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 4025,
  "fiftyTwoWeekHigh": 0.059,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.016,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 0.03847,
  "exchange": "PNK",
  "shortName": "ICO THERAPEUTICS INC",
  "longName": "iCo Therapeutics Inc.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "ICOTF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_23112550",
  "uuid": "961a2085-435c-3558-ad27-b6c643690ae2",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 153748000,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": -0.003,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.03956,
  "netIncomeToCommon": null,
  "trailingEps": -0.015,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.01101,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 152054951,
  "enterpriseValue": 5914674,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.0365,
  "logo_url": "https://logo.clearbit.com/icotherapeutics.com"
}